COLORADO – August 2025 – August 18 marks World Breast Cancer Research Day, a global observance dedicated to acknowledging the critical role of scientific research in understanding, preventing, diagnosing, and treating breast cancer. Rocky Mountain Cancer Centers (RMCC) is proud to recognize the tireless efforts of scientists, medical professionals, and advocates who are pushing the boundaries of what's possible in the fight against this disease.

A cornerstone of RMCC's ability to offer leading-edge breast cancer care is its powerful partnership with the Sarah Cannon Cancer Research Institute (SCRI). Sarah Cannon is a globally recognized network that is at the forefront of cancer research and drug development. This collaboration means that RMCC patients have direct access to more clinical trials than any other cancer facility in Colorado.

"Our partnership with Sarah Cannon allows us to bring groundbreaking therapies directly to our patients here in Colorado," said Dr. Gerlinde Tynan, a breast surgical oncologist at RMCC. "This collaboration is vital for 'seeking new answers,' a core value at RMCC. We are deeply committed to ensuring our patients have access to the most innovative and effective treatments available, often before they become widely accessible."

Through SCRI, RMCC patients can benefit from therapies tailored to specific tumor types, genetic mutations, and individual cancer diagnoses. This focus on personalized medicine is revolutionizing cancer treatment, and the partnership ensures RMCC patients are among the first to benefit. Furthermore, RMCC physicians actively serve on executive committees for breast cancer research within Sarah Cannon, demonstrating a deep engagement and leadership in shaping the future of breast cancer treatment.

"This day is about honoring the progress made through research and recognizing that there is still more work to be done," said Dr. Mabel Mardones, a medical oncologist at RMCC. "Our involvement with Sarah Cannon allows us to be at the forefront of this work. We can offer our patients hope through advanced clinical trials that lead to more personalized and effective treatments, ultimately improving their outcomes and quality of life."

RMCC’s collaboration with Sarah Cannon signifies a commitment to continuously striving to bring the most innovative treatments to the community, ensuring patients receive the highest standard of care right here at home.

For more information, please visit rockymountaincancercenters.com/clinical-trials or contact your nearest RMCC location.

RMCC is part of The U.S. Oncology Network, a highly respected national organization collaborating to advance innovative care and deliver optimal outcomes. As Colorado’s leader in cancer treatment, we’ve been delivering world-class cancer care with compassion and expertise for more than 30 years, and we make our patients’ lives easier by offering coordinated care access in 19 locations throughout Colorado. So, if you find yourself facing new challenges in your health journey, we’ll be on your side, empowering Your Courage with Our Proven Experience.

# # #

Rocky Mountain Cancer Centers (RMCC) is an independent, physician-led practice that delivers leading-edge technology and treatment options and conducts innovative research. For more than 30 years, RMCC has pioneered community-based care to enable more cancer patients to receive high-quality treatment while staying close to the support of family and friends.

Rocky Mountain Cancer Centers treats more adult cancer than any other healthcare organization in Colorado, providing 19 locations and a network of 54 physicians specializing in cancer care throughout the state. RMCC is collectively focused on treating cancer and blood disorders with advanced technology and innovative research no matter where you live, while taking a community-based approach of integrated subspecialty oncology care. This enables patients to access leading-edge treatment while living at home and receiving the critical support of family and friends.

Patients who are treated at RMCC can participate in some of the most promising national clinical trials for a broad range of cancers. RMCC has played a role in the development of more than 100 FDA-approved cancer-fighting drugs – about one-third of cancer therapies approved by the FDA to date. At any given time, more than 150 national clinical trials are open throughout The Network.

Media Contacts
RMCC Media
RMCCmedia@usoncology.com